Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
We have analysed data on exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody (NAB) assays (CPE and MxA) from the pivotal relapsing-remitting multiple sclerosis (MS) trial of interferon beta-1b (IFNB) with a longitudina...
Main Authors: | Petkau, A, White, R, Ebers, G, Reder, A, Sibley, W, Lublin, F, Paty, D, Duquette, P, Girard, M, Despault, L, DuBois, R, Knobler, R, Kelley, L, Francis, G, Lapierre, Y, Antel, J, Freedman, M, Hum, S, Greenstein, J, Mishra, B, Muldoon, J, Whitaker, J, Evans, B, Layton, B, Laguna, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2004
|
Similar Items
-
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
by: Petkau, A, et al.
Published: (2004) -
INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL
by: Duquette, P, et al.
Published: (1995) -
Treatment of multiple sclerosis with interferon beta-1b - Reply
by: Sibley, W, et al.
Published: (1997) -
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
by: Duquette, P, et al.
Published: (1996) -
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
by: Rice, G, et al.
Published: (1999)